83 related articles for article (PubMed ID: 20129451)
1. [The use of mTOR inhibitors in kidney transplantation: who are the best patients and how should these inhibitors be used?].
Büchler M
Nephrol Ther; 2009 Dec; 5 Suppl 6():S390-4. PubMed ID: 20129451
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
3. mTOR inhibition: the learning curve in kidney transplantation.
Weir MR; Diekmann F; Flechner SM; Lebranchu Y; Mandelbrot DA; Oberbauer R; Kahan BD
Transpl Int; 2010 May; 23(5):447-60. PubMed ID: 20136784
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement.
Lang UE; Heger J; Willbring M; Domula M; Matschke K; Tugtekin SM
Transplant Proc; 2009 Dec; 41(10):4285-8. PubMed ID: 20005385
[TBL] [Abstract][Full Text] [Related]
5. [Minimize kidney failure in transplantation patients with proliferation signal inhibitors].
Glowacki F; Dharancy S; Noël C; Hazzan M
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S253-6. PubMed ID: 20004331
[TBL] [Abstract][Full Text] [Related]
6. [Indications of mTOR inhibitors in liver transplantation].
Calmus Y; Dharancy S
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S245-6. PubMed ID: 20004329
[No Abstract] [Full Text] [Related]
7. Bladder cancer in patients after organ transplantation.
Wallerand H; Ravaud A; Ferrière JM
Curr Opin Urol; 2010 Sep; 20(5):432-6. PubMed ID: 20644482
[TBL] [Abstract][Full Text] [Related]
8. mTOR inhibitor-associated dermatologic and mucosal problems.
Campistol JM; de Fijter JW; Flechner SM; Langone A; Morelon E; Stockfleth E
Clin Transplant; 2010; 24(2):149-56. PubMed ID: 20236129
[TBL] [Abstract][Full Text] [Related]
9. [Liver transplantation for hepatocellular carcinoma and potential application of PSI].
Decaens T; Duvoux C
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S257-62. PubMed ID: 20004332
[TBL] [Abstract][Full Text] [Related]
10. [Side effects of proliferation signal inhibitors and their management].
Epailly E; Lorho R
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S268-74. PubMed ID: 20004334
[TBL] [Abstract][Full Text] [Related]
11. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
12. Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.
Habib N; Salaro C; Al-Ghaithi K; Phelps RG; Saggar S; Cohen SR
Int J Dermatol; 2010 Jan; 49(1):91-4. PubMed ID: 20465622
[TBL] [Abstract][Full Text] [Related]
13. Can mTOR inhibitors reduce the risk of late kidney allograft failure?
Ponticelli C
Transpl Int; 2008 Jan; 21(1):2-10. PubMed ID: 17635837
[TBL] [Abstract][Full Text] [Related]
14. Management of mTOR inhibitor side effects.
Creel PA
Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
[TBL] [Abstract][Full Text] [Related]
15. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
Nashan B
Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitors: do they help preserve renal function?
Moro J; Almenar L; Martínez-Dolz L; Agüero J; Rueda J; Arnau MA; Izquierdo M; Cano O; Sánchez-Lázaro I; Salvador A
Transplant Proc; 2007 Sep; 39(7):2135-7. PubMed ID: 17889116
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
19. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitors in polycystic kidney disease.
Watnick T; Germino GG
N Engl J Med; 2010 Aug; 363(9):879-81. PubMed ID: 20581393
[No Abstract] [Full Text] [Related]
[Next] [New Search]